GE Healthcare, NCCS collaborate to improve cancer care
GE Healthcare, the healthcare business arm of General Electric (GE), have announced a new collaboration with the National Cancer Centre Singapore (NCCS) focusing on health practices for cancer care using artificial intelligence (AI)-based research. The collaboration is the first of its kind for GE Healthcare in the Asia-Pacific (APAC) region and will see the two companies work on data analytics and clinical workflows that support care for cancer patients in APAC.
GE Healthcare will provide imaging and monitoring expertise alongside the NCCS’s support in research and development, testing, and consultation.
“NCCS is one of the region’s leading centers of excellence for cancer research and treatment, and GE Healthcare is committed to supporting them in driving the transformation and advancement of cancer care pathways in Singapore and beyond. This collaboration is an important step forward in our commitment to enabling precision health through digital technology that simplifies healthcare providers’ decision-making, accelerates care delivery, and has the potential to improve patient outcomes,” said Elie Chaillot, President & CEO Intercontinental at GE Healthcare.
“This new collaboration with NCCS is GE Healthcare’s first in the Asia-Pacific region that leverages AI-powered research to improve precision health practices for cancer care. Simplifying the way data is managed can help healthcare professionals improve patient outcomes with faster decision-making and more precise treatment options,” echoed Dr. Ben Newton, General Manager Oncology at GE Healthcare.
“The NCCS continually engages the latest digital innovations to improve the delivery of cancer care for our patients. This collaboration combines the strengths of our clinical perspective and deep expertise in oncology care, analytics and translational research with GE Healthcare’s global reach, innovative technologies and services. Working together, we hope to leverage next-generation digital tools to enhance integration of cross-disciplinary information, augment clinical decision-making, and improve outcomes for our patients,” said Associate Professor Iain Tan, Senior Consultant and Director of Research, Division of Medical Oncology, NCCS, and Principal Investigator for this collaboration.
In 2020, an estimated 19 million new cancer cases was reported worldwide, with 9.7 million or 50% of them centered in APAC, according to Global Cancer Observatory data. This collaboration is also hoped to improve access to advanced AI technologies and innovations and spur action for more tailored treatment options for specific cancer types in APAC and beyond.
